NCT01046955.
Methods | Randomised, open‐label, parallel assignment (phase 4) |
Participants | 38 participants, age > 14 years, 1st LD kidney transplant recipients |
Interventions | ATG versus alemtuzumab versus daclizumab |
Outcomes | Primary: effectiveness and toxicity at 3 years, patient and graft survival at 1 and 3 years Secondary: incidence of adverse reactions at 1 and 3 years |
Notes | This study has been completed but no study results have been posted on Clinicaltrials.gov |